Literature DB >> 34297164

Endometrial cancer from early to advanced-stage disease: an update for radiologists.

Cibele Luna1, Patricia Balcacer2, Patricia Castillo2, Marilyn Huang3, Francesco Alessandrino2.   

Abstract

The purpose of this article is to review the current molecular classification of endometrial cancer, the imaging findings in early and advanced disease, and the current management strategies, focusing on the new systemic therapies for advanced EC. In recent years, the management of endometrial cancer has significantly changed. The molecular characterization of endometrial cancer has shed new light into the biologic behavior of this disease, the International Federation of Gynecology and Obstetrics staging system was recently revised, and imaging was formally incorporated in the management of endometrial cancer. Recent genomic analysis of endometrial cancer led to the approval of new molecular-targeted therapies and immune checkpoint inhibitors. Imaging allows assessment of myometrial invasion, cervical stromal extension, lymph node involvement and distant metastases, and has a crucial role for treatment planning. Treatment strategies, which include surgery, radiation and systemic therapies are based on accurate staging and risk stratification.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Endometrial cancer; FIGO staging; MR imaging; Molecular subtypes

Mesh:

Year:  2021        PMID: 34297164     DOI: 10.1007/s00261-021-03220-7

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  63 in total

Review 1.  Molecular approaches for classifying endometrial carcinoma.

Authors:  Josep M Piulats; Esther Guerra; Marta Gil-Martín; Berta Roman-Canal; Sonia Gatius; Rebeca Sanz-Pamplona; Ana Velasco; August Vidal; Xavier Matias-Guiu
Journal:  Gynecol Oncol       Date:  2016-12-29       Impact factor: 5.482

Review 2.  Current recommendations and recent progress in endometrial cancer.

Authors:  Rebecca A Brooks; Gini F Fleming; Ricardo R Lastra; Nita K Lee; John W Moroney; Christina H Son; Ken Tatebe; Jennifer L Veneris
Journal:  CA Cancer J Clin       Date:  2019-05-10       Impact factor: 508.702

Review 3.  Management Strategies for Recurrent Endometrial Cancer.

Authors:  Elizabeth V Connor; Peter G Rose
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-04       Impact factor: 4.512

4.  Reclassifying endometrial carcinomas with a combined morphological and molecular approach.

Authors:  Joseph Carlson; W Glenn McCluggage
Journal:  Curr Opin Oncol       Date:  2019-09       Impact factor: 3.645

5.  FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis.

Authors:  Shaily Arora; Sanjeeve Balasubramaniam; Wei Zhang; Lijun Zhang; Rajeshwari Sridhara; Dianne Spillman; Jaigi P Mathai; Bradley Scott; Sarah J Golding; Michael Coory; Richard Pazdur; Julia A Beaver
Journal:  Clin Cancer Res       Date:  2020-04-15       Impact factor: 12.531

Review 6.  The revised FIGO staging system for uterine malignancies: implications for MR imaging.

Authors:  Susan J Freeman; Ahmed M Aly; Masako Y Kataoka; Helen C Addley; Caroline Reinhold; Evis Sala
Journal:  Radiographics       Date:  2012-10       Impact factor: 5.333

7.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

Review 8.  Molecular Genetics of Endometrial Carcinoma.

Authors:  Daphne W Bell; Lora Hedrick Ellenson
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

9.  Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers.

Authors:  Megan A Clarke; Susan S Devesa; Summer V Harvey; Nicolas Wentzensen
Journal:  J Clin Oncol       Date:  2019-05-22       Impact factor: 44.544

10.  Natural history of recurrences in endometrial carcinoma.

Authors:  Bengt Sorbe; Christian Juresta; Cecilia Ahlin
Journal:  Oncol Lett       Date:  2014-07-18       Impact factor: 2.967

View more
  3 in total

1.  Lower expression of PDZRN3 induces endometrial carcinoma progression via the activation of canonical Wnt signaling.

Authors:  Qiuhong Li; Jie Zhong; Shangjie Yang; Yanping Liang
Journal:  Oncol Lett       Date:  2022-01-27       Impact factor: 2.967

2.  Single cell sequencing analysis and transcriptome analysis constructed the liquid-liquid phase separation(LLPS)-related prognostic model for endometrial cancer.

Authors:  Jiayang Wang; Fei Meng; Fei Mao
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

3.  Association between subtypes of metabolic syndrome and prognosis in patients with stage I endometrioid adenocarcinoma: A retrospective cohort study.

Authors:  Man-Qi Chen; Hai-Xue Lin; Jin-Xiao Liang; Miao-Fang Wu; Jing Li; Li-Juan Wang
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.